title: Targeted therapies: What have we learned from SHIVA?
authors.affiliation: Department of Medical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France, and 35 rue Dailly, 92210 Saint-Cloud, France; and at the EA7285 unit, Versailles-Saint-Quentin-en-Yvelines University, 2 avenue de la Source de la Bièvre, 78180 Montigny-le-Bretonneux, France.
authors.forename: Christophe
authors.initials: C
authors.lastname: Le Tourneau
authors.affiliation: Center for Personalized Cancer Therapy and the Division of Haematology and Oncology, UCSD Moores Cancer Center, 3855 Health Sciences Dr # 987, La Jolla, California 92093, USA.
authors.forename: Razelle
authors.initials: R
authors.lastname: Kurzrock
mesh_terms: D000465:Algorithms; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D057285:Precision Medicine / Q000379:methods; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D012107:Research Design
chemical_list: D000970:Antineoplastic Agents